Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
July 30, 2015 7:00 AM EDTRevenues of $5.0 billion, in line with the second quarter of 2014. Non-GAAP operating income of $1.6 billion, an increase of 16% compared to the second quarter of 2014. GAAP operating income of $662 million, down 28%. Non-GAAP net income of $1.2 billion, up 15% compared to the second quarter of 2014. GAAP net income of $539 million, a decrease of 28%. Quarterly non-GAAP EPS of $1.43, an increase of 14% compared to the second quarter of 2014. GAAP diluted EPS of $0.63, a decrease of 28%. Strong cash flow from operations of $1.5 billion, an increase of 41%... More
